Manufacturer

Dr. Reddy's Laboratories, Inc.

163 recalls in our database name Dr. Reddy's Laboratories, Inc. as the manufacturing or recalling firm.

What the numbers show

Total: 163
Critical: 0
Severe: 30
Most recent: 2025-12-17

Of the 163 recalls from Dr. Reddy's Laboratories, Inc. we have scored against our rubric, 0 (0%) are Critical — deaths or serious injuries reported, or the agency’s own highest classification — and 30 (18%) are Severe.

About this listing

The manufacturer string comes from the agency’s own source notice — for FDA recalls, the “recalling firm” field; for NHTSA recalls, the vehicle manufacturer; for CPSC recalls, the firm-of-record on the joint press release. A single corporate family can appear under multiple manufacturer strings as agency notices aren’t standardized on a canonical name. If you don’t see recalls you expect, try a parent-company search or a broader full-text search.

Severity scores below are computed from the agency’s classification and the recall text, never from manufacturer behaviour or history. Many manufacturers issue routine corrective actions (software updates, labelling corrections) that are correctly scored low — having recalls on this list isn’t inherently a quality signal.

51–75 of 163

ModerateFDA (Drugs)·D-0267-2022·2021-12-15
Allergy and Congestion tablets recalled due to failed dissolution specifications
Dr. Reddy's Laboratories is recalling Allergy and Congestion (Fexofenadine HCl 60 mg & Pseudoephedrine HCl 120 mg) Extended-Release Tablets because they failed to meet dissolution specifications. Approximately 4,896 cartons distributed nationwide are affected.
Product
ALLERGY AND CONGESTION — ALLERGY AND CONGESTION (FEXOFENADINE HCL AND PSEUDOEPHEDRINE HCI)
Category
Drug
Distribution
Distributed nationwide
ModerateFDA (Drugs)·D-0270-2022·2021-12-15
Fexofenadine and Pseudoephedrine Tablets Recalled for Failed Dissolution
Dr. Reddy's Laboratories is recalling Fexofenadine HCl 60 mg and Pseudoephedrine HCl 120 mg Extended Release Tablets because they failed dissolution specifications, which may affect how the medication works in the body.
Product
Antihistamine & Nasal Decongestant, Fexofenadine HCl 60 mg and Pseudoephedrine HCl 120 mg, Extended Release Tablets USP, Allergy & Congestion, 12 Hour, 20 Tablets, Distributed by: Rugby Laboratories, 17177 N. Laurel Park Drive, Suite 233, Livonia, MI 48152, www.rugbylaboratories.
Category
Drug
Distribution
Distributed nationwide
ModerateFDA (Drugs)·D-0271-2022·2021-12-15
Antihistamine and Decongestant Tablets Recalled for Failed Dissolution
Dr. Reddy's Laboratories is recalling Fexofenadine HCl 60 mg and Pseudoephedrine HCl 120 mg extended-release tablets distributed by Rugby Laboratories due to failed dissolution specifications. Affected lot AC2103329D (Exp 1/2023) was distributed nationwide in 2,184 cartons.
Product
Antihistamine & Nasal Decongestant, Fexofenadine HCl 60 mg and Pseudoephedrine HCl 120 mg, Extended Release Tablets USP, Allergy & Congestion, 12 Hour, 30 Tablets, Distributed by: Rugby Laboratories, 17177 N. Laurel Park Drive, Suite 233, Livonia, MI 48152, www.rugbylaboratories.
Category
Drug
Distribution
Distributed nationwide
ModerateFDA (Drugs)·D-0269-2022·2021-12-15
OTC Allergy and Congestion Tablets Recalled for Failed Dissolution
Dr. Reddy's Laboratories is recalling 5,016 cartons of Fexofenadine HCl 60 mg / Pseudoephedrine HCl 120 mg Extended Release Tablets nationwide due to failed dissolution specifications. Affected lot is AC2103329F with expiration 1/2023.
Product
FEXOFENADINE HCL AND PSEUDOEPHEDRINE HCI — FEXOFENADINE HCL AND PSEUDOEPHEDRINE HCI (FEXOFENADINE HCL AND PSEUDOEPHEDRINE HCI)
Category
Drug
Distribution
Distributed nationwide
LowFDA (Drugs)·D-0273-2022·2021-12-15
CVS Allergy Relief D Extended-Release Tablets Recall
CVS Allergy Relief D extended-release tablets (Fexofenadine HCl 60 mg / Pseudoephedrine HCl 120 mg) are being recalled because they failed dissolution specifications, meaning the tablets may not release the medication properly.
Product
Allergy Relief D Fexofenadine HCl, 60 mg I Pseudoephedrine HCl, 120 mg, Extended Release Tablets, 30 Extended-Release Tablets USP, Distributed By CVS Pharmacy Inc., One CVS Drive, Woonsocket, RI 02985, Made in India, NDC 69842-249-30
Category
Drug
Distribution
Distributed nationwide
LowFDA (Drugs)·D-0268-2022·2021-12-15
CVS Allergy & Congestion Relief Tablets Recalled for Failed Dissolution
Dr. Reddy's Laboratories is recalling CVS Allergy & Congestion Relief tablets (fexofenadine HCl 60 mg/pseudoephedrine HCl 120 mg extended-release) nationwide due to failed dissolution specifications.
Product
Allergy & Congestion Relief Allergy Relief D, Fexofenadine HCl 60 mg/ Pseudoephedrine HCl 120 mg Extended Release Tablets, 20 extended-release tablets, Distributed by: CVS Pharmacy, Inc., One CVS Drive, Woonsocket, RI 02895, Made in India, NDC 69842-249-20
Category
Drug
Distribution
Distributed nationwide
LowFDA (Drugs)·D-0272-2022·2021-12-15
Fexofenadine and Pseudoephedrine allergy relief tablets recalled for failed dissolution
Dr. Reddy's Laboratories is recalling a 12 HR Allergy & Congestion Relief product distributed nationwide because the tablets failed to meet dissolution specifications, which may affect drug effectiveness.
Product
12 HR Allergy & Congestion Relief Fexofenadine HCl, 60 mg I Pseudoephedrine HCl, 120 mg Antihistamine I Nasal Decongestant, 20 Extended-Release Tablets USP, Distributed By Cardinal Health, Dublin, Ohio 43107, Made in India, NDC 70000-0518-1.
Category
Drug
Distribution
Distributed nationwide
LowFDA (Drugs)·D-0275-2022·2021-12-15
Fexofenadine and Pseudoephedrine Tablets Recalled for Failed Dissolution
Dr. Reddy's Laboratories is recalling Fexofenadine HCl 60 mg and Pseudoephedrine HCl 120 mg extended-release tablets because they failed to meet dissolution specifications, which may affect how the medication works in the body.
Product
FEXOFENADINE HCL AND PSEUDOEPHEDRINE HCI — FEXOFENADINE HCL AND PSEUDOEPHEDRINE HCI (FEXOFENADINE HCL AND PSEUDOEPHEDRINE HCI)
Category
Drug
Distribution
Distributed nationwide
ModerateFDA (Drugs)·D-0084-2022·2021-11-10
Dr. Reddy's Ezetimibe and Simvastatin Tablets Recalled for Failed Excipient Specifications
Dr. Reddy's Laboratories is recalling Ezetimibe and Simvastatin 10 mg/40 mg tablets because an excipient used in manufacturing failed conductivity specifications. The recall affects 11,590 bottles of 30-count and 3,585 bottles of 90-count packages distributed nationwide.
Product
EZETIMIBE AND SIMVASTATIN — EZETIMIBE AND SIMVASTATIN (EZETIMIBE AND SIMVASTATIN)
Category
Drug
Distribution
Distributed nationwide
ModerateFDA (Drugs)·D-0081-2022·2021-11-10
Dr. Reddy's Ezetimibe and Simvastatin Tablets Recalled for Excipient Specification Failure
Dr. Reddy's Laboratories is recalling Ezetimibe and Simvastatin 10 mg/10 mg tablets nationwide because the product was manufactured using an excipient that failed to meet conductivity specifications.
Product
EZETIMIBE AND SIMVASTATIN — EZETIMIBE AND SIMVASTATIN (EZETIMIBE AND SIMVASTATIN)
Category
Drug
Distribution
Distributed nationwide
ModerateFDA (Drugs)·D-0085-2022·2021-11-10
Dr. Reddy's Ezetimibe and Simvastatin Tablets Recalled for Failed Excipient Specifications
Dr. Reddy's Laboratories is recalling 696 bottles of Ezetimibe and Simvastatin Tablets (10 mg/40 mg) distributed nationwide due to failed excipient specifications and the presence of foreign tablets in bottles.
Product
EZETIMIBE AND SIMVASTATIN — EZETIMIBE AND SIMVASTATIN (EZETIMIBE AND SIMVASTATIN)
Category
Drug
Distribution
Distributed nationwide
ModerateFDA (Drugs)·D-0083-2022·2021-11-10
Dr. Reddy's Ezetimibe and Simvastatin Tablets Recalled for Failed Excipient Specifications
Dr. Reddy's Laboratories is recalling Ezetimibe and Simvastatin Tablets (10 mg/80 mg) because the product was manufactured using an excipient that failed to meet conductivity specifications.
Product
EZETIMIBE AND SIMVASTATIN — EZETIMIBE AND SIMVASTATIN (EZETIMIBE AND SIMVASTATIN)
Category
Drug
Distribution
Distributed nationwide
ModerateFDA (Drugs)·D-0082-2022·2021-11-10
Dr. Reddy's Ezetimibe and Simvastatin Tablets Recalled for Failed Excipient Specifications
Dr. Reddy's Laboratories is recalling Ezetimibe and Simvastatin Tablets (10 mg/20 mg) nationwide because the product was manufactured using an excipient that failed conductivity specifications.
Product
EZETIMIBE AND SIMVASTATIN — EZETIMIBE AND SIMVASTATIN (EZETIMIBE AND SIMVASTATIN)
Category
Drug
Distribution
Distributed nationwide
ModerateFDA (Drugs)·D-0026-2022·2021-10-27
Omeprazole Magnesium Acid Reducer Capsules Recalled for Staple Contamination
Dr. Reddy's Laboratories is recalling Acid Reducer (Omeprazole Magnesium) 20 mg capsules nationwide because staples have been found co-mingled with capsules in bottles.
Product
ACID REDUCER — ACID REDUCER (OMEPRAZOLE MAGNESIUM)
Category
Drug
Distribution
Distributed nationwide
ModerateFDA (Drugs)·D-0750-2021·2021-08-25
Tizanidine Tablets Recalled for Failed Specifications Due to Shaved Tablets
Dr. Reddy's Laboratories is recalling Tizanidine HCl 4 mg tablets nationwide because some tablets are shaved, failing the required tablet specification.
Product
TIZANIDINE — TIZANIDINE (TIZANIDINE)
Category
Drug
Distribution
Distributed nationwide
ModerateFDA (Drugs)·D-0629-2021·2021-06-23
Dr. Reddy's Atorvastatin Calcium Tablets Recalled for Failed Impurity Specifications
Dr. Reddy's Laboratories is recalling Atorvastatin Calcium Tablets USP 10 mg nationwide because certain lots contain impurities that exceeded acceptable specifications.
Product
ATORVASTATIN CALCIUM — ATORVASTATIN CALCIUM (ATORVASTATIN CALCIUM)
Category
Drug
Distribution
Distributed nationwide
LowFDA (Drugs)·D-0599-2021·2021-06-02
Dr. Reddy's Recalls Atorvastatin Calcium Tablets Due to Impurities
Dr. Reddy's Laboratories is recalling Atorvastatin Calcium 10 mg tablets due to the presence of degradation impurities.
Product
ATORVASTATIN CALCIUM — ATORVASTATIN CALCIUM (ATORVASTATIN CALCIUM)
Category
Drug
Distribution
Distributed nationwide
ModerateFDA (Drugs)·D-0292-2021·2021-03-10
Dr. Reddy's Recalls Progesterone Capsules Due to Dissolution Failures
Dr. Reddy's Laboratories is recalling 16,449 bottles of 200 mg Progesterone Capsules because stability testing revealed out-of-specification dissolution results.
Product
PROGESTERONE — PROGESTERONE (PROGESTERONE)
Category
Drug
Distribution
Distributed nationwide
LowFDA (Drugs)·D-0291-2021·2021-03-10
Dr. Reddy's Recalls Atorvastatin Calcium Tablets Due to Impurities
Dr. Reddy's Laboratories is recalling Atorvastatin Calcium tablets because they contain impurities that exceed FDA specifications.
Product
ATORVASTATIN CALCIUM — ATORVASTATIN CALCIUM (ATORVASTATIN CALCIUM)
Category
Drug
Distribution
Distributed nationwide
ModerateFDA (Drugs)·D-0287-2021·2021-03-03
Dr. Reddy's Recalls Imatinib Mesylate Tablets for Dissolution Failures
Dr. Reddy's Laboratories is recalling specific lots of Imatinib Mesylate 100mg tablets because they failed to meet required dissolution specifications.
Product
IMATINIB — IMATINIB (IMATINIB)
Category
Drug
Distribution
Distributed nationwide
LowFDA (Drugs)·D-1256-2020·2020-05-06
Dr. Reddy's Recalls Esomeprazole Magnesium Capsules Due to Discoloration
Dr. Reddy's Laboratories is recalling 1,752 bottles of Esomeprazole Magnesium 40 mg capsules because the product contains brown pellets.
Product
ESOMEPRAZOLE MAGNESIUM — ESOMEPRAZOLE MAGNESIUM (ESOMEPRAZOLE MAGNESIUM)
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-1094-2020·2020-04-08
Dr. Reddy's Recalls Phytonadione Ampules Due to Breaking and Shattering
Dr. Reddy's is recalling Phytonadione Injectable Emulsion ampules because they may break or shatter when opened.
Product
PHYTONADIONE — PHYTONADIONE (PHYTONADIONE)
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-0177-2020·2019-11-13
Dr. Reddy's Recalls Ranitidine Tablets Due to NDMA Impurity
Dr. Reddy's Laboratories is recalling specific bottles of Ranitidine Tablets 150 mg because an NDMA impurity was detected.
Product
Ranitidine Tablets, USP 150 mg, a.) 24 count bottles (NDC 71713-203-02), b.)95 count bottles (NDC 71713-203-05) (Thirty Madison) OTC.
Category
Drug
Distribution
0 states
SevereFDA (Drugs)·D-0175-2020·2019-11-13
Dr. Reddy's Recalls Ranitidine Tablets Due to NDMA Impurity
Dr. Reddy's Laboratories is recalling Ranitidine Tablets 75 mg because the presence of the NDMA impurity was detected in the product.
Product
Ranitidine Tablets 75 mg, a.) 30 count bottles (NDC 63868-482-30), 60 count bottles (NDC 63868-482-60) (CDMA) OTC
Category
Drug
Distribution
0 states
SevereFDA (Drugs)·D-0183-2020·2019-11-13
Dr. Reddy's Recalls Ranitidine Tablets Due to NDMA Impurity
Dr. Reddy's Laboratories is recalling Ranitidine Tablets 75 mg because of the presence of the NDMA impurity.
Product
Ranitidine Tablets, USP 75 mg, a.) 30- count bottles (NDC 0363-0131-30), b.) 80-count bottles (NDC 0363-0131-80) (Walgreens) OTC
Category
Drug
Distribution
0 states

About this company

Community-sourced company facts from Wikidata, not from any recall agency. This is background on the corporate entity — it says nothing about the recall(s) listed on this page, which come from the agency source notice above.

Dr Reddy's Laboratories (Switzerland)

Country: Switzerland
Parent company: Dr. Reddy's Laboratories

Source: Wikidata (Q30343911), licensed CC0. Wikidata is community-edited and may not reflect the current corporate structure.